Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 180 matching trials from the live ClinicalTrials.gov search.
Active, not recruiting No phase listed Observational

Perfusion Abnormalities in Hypertrophic Cardiomyopathy

NCT06599229
Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
myocardial contrast echo
Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Recruiting Not applicable Interventional

ELEVATE-HFpEF Clinical Study

NCT06678841
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Personalized cardiac pacing
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
40 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
26
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 22 more
Conditions
Heart Failure, Cardiomyopathy, Hypertrophic, Left Ventricular Hypertrophy
Interventions
Software
Device
Lead sponsor
Prolaio
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Hypertrophic Cardiomyopathy
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
Up to 20 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
12
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 9 more
Conditions
Hypertrophic Cardiomyopathy
Interventions
Not listed
Lead sponsor
American Heart Association
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Fairhope, Alabama • Kankakee, Illinois • Baltimore, Maryland + 3 more
Conditions
Hypertrophic Cardiomyopathy
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
Mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Heart Failure, Reduced Ejection Fraction
Interventions
sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696), matching placebo enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more
Conditions
Cardiomyopathy
Interventions
Not listed
Lead sponsor
Tenaya Therapeutics
Industry
Eligibility
0 Years to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
21
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 17 more
Conditions
Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure, Cardiomyopathies
Interventions
MYDICAR Phase 1, MYDICAR Phase 2, Placebo Phase 2 only
Genetic
Lead sponsor
Celladon Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
4
States / cities
La Jolla, California • San Diego, California • Kansas City, Missouri + 1 more
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
Mavacamten, Non-mavacamten symptomatic oHCM therapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
60
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 48 more
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg), Placebo to match metoprolol succinate
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
28
States / cities
Anchorage, Alaska • Phoenix, Arizona • La Jolla, California + 21 more
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten
Drug
Lead sponsor
Michael Ayers
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Coronary Artery Disease
Interventions
Emerge™ 1.20 mm PTCA Dilatation Catheter
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Atlanta, Georgia
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in Aortic Stenosis - B.A.S.S.

NCT01334801
Conditions
Aortic Stenosis, Disorder of Prosthetic Cardiac Valve, Aortic Valve Insufficiency, Mitral Valve Insufficiency, Hypertrophic Cardiomyopathy, Tricuspid Valve Insufficiency
Interventions
Blood Draw
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Hypertrophic Cardiomyopathy
Interventions
Echo and myocardial contrast echocardiography perfusion imaging
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
19 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Cardiovascular Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
13 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Tenafly, New Jersey
Active, not recruiting Not applicable Interventional

Sodium Lowering Vascular Effects Trial

NCT05388032
Conditions
Endothelial Dysfunction, Vascular Stiffness, Left Ventricular Hypertrophy, Left Ventricular Dysfunction
Interventions
Sodium Reduction Intervention
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
40 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Cardiomyopathies, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy, Left Ventricular Non-compaction Cardiomyopathy
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Hypertrophic Cardiomyopathy, Left Ventricular Septal Hypertrophy, Mitral Valve Disease, Aortic Valve Stenosis
Interventions
Septal Scoring Along Midline Endocardium
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
Approved Hypertrophic Cardiomyopathy drug treatments, Mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Hypertrophic Cardiomyopathy
Interventions
pacemaker implantation, percutaneous transluminal septal ablation (PTSA)
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Healthy Participants
Interventions
Mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Miami, Florida • Saint Paul, Minnesota